Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Clinical Trial
Official title:
Explore the Efficacy and Safety of Dalpiciclib Combined With Fluvestrant and Compound Gossypol Acetate Tablets in Advanced HR-positive and HER2-negative Breast Cancer After CDK4/6 Treatment Failed.
This is a single-arm, Phase II clinical study to explore the efficacy and safety of dalpiciclib combined with fluvestrant and compound gossypol acetate tablets in advanced HR-positive and HER2-negative breast cancer after CDK4/6 treatment failed.
Dalpiciclib: According to the standard dose, 150mg orally for three weeks and stop for one week. Fluvestrant: At the standard dose, 500mg once every four weeks. A further 500mg dose two weeks after the first dose. Compound gossypol acetate tablets: 20mg once a day. ;